DCVAC/OvCa

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameDCVAC/OvCa

Drug Alias NameDendritic cell vaccine/Ovarian cancer (Sotio)DCVAC/OvCa

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaPolandGermany

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSotio

China Registration ClassN/A

Develop Information

Active CompaniesSotio As

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsCarcinoma, Ovarian Epithelial

Inactive IndicationsFallopian Tube NeoplasmsPeritoneal Neoplasms

Other Information

ATC CodeN/A